In a clinical trial, patients with mild cases of COVID-19 are randomly assigned to either a placebo or a standard anti-malaria drug. The number of patients who develop heart arrhythmias are tabulated in Table 13.11, subdivided by age group.

(a) Plot the ln(odds) of developing an arrhythmia in the same style as a cell-mean plot for a two-way ANOVA.

(b) Use a logistic model to analyze this data, interpreting all the significant effects.

Transcribed Image Text:

Table 13.11 Incidence of heart arrhythmias for practice Exercise 1. Age group 30 to 49 Age group 50 to 69 Placebo Drug Placebo Drug No arrhythmia Arrhythmia 390 388 581 558 10 12 19 42 Total 400 400 600 600